How Does Cobenfy Work, and How Is It Different From Other Medicines Used to Treat Schizophrenia? An imbalance of brain chemicals called neurotransmitters may contribute to schizophrenia.

Cobenfy is also in phase 3 clinical testing ... currently in two phase 2 studies. It offers once-daily dosing, versus twice-daily with BMS' drug and, according to some assessments, could be ...

The Food and Drug Administration approved the first new drug in over 30 years to treat schizophrenia in adults. The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers ...

Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...

Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell in line with analyst expectations. Bristol Myers Squibb, which acquired ...

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older therapies, writes Julie Coleman for CNBC..Bristol ...

The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers Squibb, a global biopharmaceutical company. The drug became available by prescription in retail pharmacies across ...